|
|
|
|
|
|
|
|
Full text
Conclusion
Our data suggest that patients should be screened for PARP1 expression prior to therapy
with PARP inhibitors. Further, the observed reduction of intratumoral PARP1 post-chemotherapy
suggests that treating chemo-naïve patients with PARP inhibitors prior to the administration
of chemotherapy, or concurrently, might increase the responsiveness to PARP1 inhibition.
Thus, a change in the timing of PARP inhibitor administration may be warranted for
future clinical trials.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.